Cervix carcinoma stage III – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 12:23:12 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Cervix carcinoma stage III – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Effectiveness of Carboplatin and Paclitaxel in Treating Cervical Cancer with Para-aortic Lymph Node Involvement https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-carboplatin-and-paclitaxel-in-treating-cervical-cancer-with-para-aortic-lymph-node-involvement/ Wed, 29 Apr 2026 14:28:59 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-carboplatin-and-paclitaxel-in-treating-cervical-cancer-with-para-aortic-lymph-node-involvement/ This clinical trial is focused on studying the treatment of Cervical Cancer, specifically in cases where the cancer has spread to the para-aortic lymph nodes. The trial will use a combination of two medications: Paclitaxel and Carboplatin. These medications are given as a solution through an intravenous infusion, which means they are delivered directly into the bloodstream through a vein. The purpose of the study is to determine if starting treatment with these medications, followed by the usual treatment of chemoradiotherapy, can improve the overall survival of patients compared to receiving the usual treatment alone.

Participants in the study will first receive three cycles of the medications Paclitaxel and Carboplatin. After this initial phase, they will continue with the standard treatment, which involves a combination of chemotherapy and radiation therapy given at the same time. This approach is known as concurrent chemoradiotherapy. The study will compare the outcomes of patients who receive this additional initial treatment with those who only receive the standard treatment.

The trial aims to assess various outcomes, including overall survival, which is the time from the start of the study until death from any cause. It will also look at how well the tumor responds to the treatment, the time until the cancer progresses or returns, and the quality of life of the participants. Additionally, the study will monitor any side effects that occur during the treatment. The trial is expected to continue until January 2028.

]]>